Loading...
•
Dec 31, 2021
Lineage Q4 2021 Earnings Report
Reported fourth quarter and full year 2021 financial results and provided a business update.
Key Takeaways
Lineage Cell Therapeutics reported total revenues of $1.2 million for the fourth quarter ended December 31, 2021, an increase of $0.8 million compared to the same period in 2020. The net loss attributable to Lineage for the three months ended December 31, 2021 was ($29.0) million, or ($0.17) per share (basic and diluted). Cash and cash equivalents totaled $55.7 million as of December 31, 2021.
Entered into a worldwide corporate partnership with Roche and Genentech for the OpRegen program.
Continued to execute on the strategic plan to position Lineage as a leader in the allogeneic cell transplant revolution.
The collaboration with Roche and Genentech brings significant validation to the technology platform and approach to product development.
The transaction adds significant new capital to help support the advancement of the OPC1 program, VAC platform, and the expansion of the regenerative medicine pipeline.
Forward Guidance
Lineage's corporate objectives in 2022 will be focused on the continued advancement of current clinical programs and making responsible investments in the expansion of its novel approach to cell transplant medicine in disease settings where they believe they can make a meaningful impact. They look forward to announcing a new, internally developed pipeline candidate later this quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...